Eosinophilic granulomatosis with polyangiitis
- Allergic granulomatous and angiitis
- Allergic angiitis and granulomatosis
- Allergic granulomatosis
- Churg-Strauss vasculitis
News & Events
On this page
NCATS Co-Sponsored Conferences
American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, Wednesday, May 04, 2016 - Saturday, May 07, 2016
Location: Washington, DC
Description: Save the date and plan to head to Washington, DC on May 4-7, 2016, for the premiere gene and cell therapy conference in the world. Taking place at the Marriott Wardman Park Hotel, the ASGCT 19th Annual Meeting will feature ground breaking clinical trial results, cutting edge technology advancements, social networking events, and much more. Join over 1,900 of the worlds top gene and cell therapy professionals for four full days of educational offerings including plenary lectures given by Dr. David R. Liu and 2015 Japan Prize recipients, Dr. Alain Fischer, and Dr. Theodore Friedmann.
8th International Eosinophil Society’s Biennial Symposium, Saturday, July 13, 2013 - Wednesday, July 17, 2013
Location: Oxford, England
Description: IES Symposium organizers’ central goal is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of allergy, immunology, hematology, and cancer in relation to the role of the eosinophil in health and disease.
Eosinophil-Associated Disease: Approaches to Treatment , Wednesday, May 25, 2005 - Thursday, May 26, 2005
Location: University Hospital, Bern, Switzerland
Description: Idiopathic hypereosinophilic syndromes (HESs), including idiopathic HES, familial hypereosinophilia, Churg-Strauss vasculitis, and eosinophil-associated gastrointestinal disorders (EGID), are a heterogeneous group of rare disorders that are characterized by marked eosinophilia in the peripheral blood and/or tissues without identifiable cause. The goals of this conference were to bring together clinicians and scientists with expertise in the treatment of the various idiopathic hypereosinophilic disorders in order to summarize and discuss available data on efficacy and side effects of the therapeutic agents and modalities currently in use for the treatment of selected HESs, with the goal of identifying a consensus approach; to identify novel agents and/or strategies for use in future clinical trials; and to continue to expand the consortium of clinical researchers and available resources for collaborative study established at the prior workshop on the diagnosis of eosinophilic disorders in order to foster the development of multicenter protocols to study the pathogenesis and treatment of idiopathic hypereosinophilic disorders. Participants addressed the state of currently available therapies for three idiopathic HESs, taking into account recent developments in diagnostic testing, advances in the understanding of the pathogenesis of hypereosinophilic conditions, and novel strategies for the treatment of idiopathic eosinophilic disorders.